The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide
Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutami...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/4/772 |
| _version_ | 1797298622234099712 |
|---|---|
| author | So Nakamura Masayoshi Nagata Naoya Nagaya Takeshi Ashizawa Hisashi Hirano Yan Lu Hisamitsu Ide Shigeo Horie |
| author_facet | So Nakamura Masayoshi Nagata Naoya Nagaya Takeshi Ashizawa Hisashi Hirano Yan Lu Hisamitsu Ide Shigeo Horie |
| author_sort | So Nakamura |
| collection | DOAJ |
| description | Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutamide administration. A retrospective subgroup analysis and prognostic survey were conducted on 43 patients with mCRPC and bone metastases treated in Juntendo University-affiliated hospitals from 2015 to 2022. Patients were treated with 160 mg enzalutamide daily. CTC analyses on blood samples were performed regularly before and every three months after treatment. The relationship between the patients’ clinical factors and the OS rate was analyzed using the log-rank test; the median OS was 37 months. Patients with no detected CTCs at baseline showed significantly longer OS than those with detectable CTCs at baseline. Furthermore, patients demonstrating negative reversion of CTCs during enzalutamide treatment had significantly longer OS than patients with CTC-positivity. Two biomarkers—higher hemoglobin at baseline and achieving negative reversion of CTCs—were significantly associated with prolonged OS. This study suggests that patients achieving CTC-negative reversion during treatment for mCRPC with bone metastases exhibit improved long-term OS. Chronological measurement of CTC status might be clinically useful in the treatment of mCRPC. |
| first_indexed | 2024-03-07T22:38:41Z |
| format | Article |
| id | doaj.art-76313047326e4547bf8e9a3427fa8b98 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-07T22:38:41Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-76313047326e4547bf8e9a3427fa8b982024-02-23T15:10:50ZengMDPI AGCancers2072-66942024-02-0116477210.3390/cancers16040772The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by EnzalutamideSo Nakamura0Masayoshi Nagata1Naoya Nagaya2Takeshi Ashizawa3Hisashi Hirano4Yan Lu5Hisamitsu Ide6Shigeo Horie7Department of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanDepartment of Advanced Informatics of Genetic Diseases, Digital Therapeutics, Juntendo University Graduate School of Medicine, Tokyo 1138-421, JapanDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo 1138-431, JapanEnzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutamide administration. A retrospective subgroup analysis and prognostic survey were conducted on 43 patients with mCRPC and bone metastases treated in Juntendo University-affiliated hospitals from 2015 to 2022. Patients were treated with 160 mg enzalutamide daily. CTC analyses on blood samples were performed regularly before and every three months after treatment. The relationship between the patients’ clinical factors and the OS rate was analyzed using the log-rank test; the median OS was 37 months. Patients with no detected CTCs at baseline showed significantly longer OS than those with detectable CTCs at baseline. Furthermore, patients demonstrating negative reversion of CTCs during enzalutamide treatment had significantly longer OS than patients with CTC-positivity. Two biomarkers—higher hemoglobin at baseline and achieving negative reversion of CTCs—were significantly associated with prolonged OS. This study suggests that patients achieving CTC-negative reversion during treatment for mCRPC with bone metastases exhibit improved long-term OS. Chronological measurement of CTC status might be clinically useful in the treatment of mCRPC.https://www.mdpi.com/2072-6694/16/4/772circulating tumor cells (CTCs)enzalutamidebone metastasescastration-resistant prostate cancerandrogen receptor signaling inhibitor |
| spellingShingle | So Nakamura Masayoshi Nagata Naoya Nagaya Takeshi Ashizawa Hisashi Hirano Yan Lu Hisamitsu Ide Shigeo Horie The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide Cancers circulating tumor cells (CTCs) enzalutamide bone metastases castration-resistant prostate cancer androgen receptor signaling inhibitor |
| title | The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide |
| title_full | The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide |
| title_fullStr | The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide |
| title_full_unstemmed | The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide |
| title_short | The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide |
| title_sort | detection and negative reversion of circulating tumor cells as prognostic biomarkers for metastatic castration resistant prostate cancer with bone metastases treated by enzalutamide |
| topic | circulating tumor cells (CTCs) enzalutamide bone metastases castration-resistant prostate cancer androgen receptor signaling inhibitor |
| url | https://www.mdpi.com/2072-6694/16/4/772 |
| work_keys_str_mv | AT sonakamura thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT masayoshinagata thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT naoyanagaya thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT takeshiashizawa thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT hisashihirano thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT yanlu thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT hisamitsuide thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT shigeohorie thedetectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT sonakamura detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT masayoshinagata detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT naoyanagaya detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT takeshiashizawa detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT hisashihirano detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT yanlu detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT hisamitsuide detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide AT shigeohorie detectionandnegativereversionofcirculatingtumorcellsasprognosticbiomarkersformetastaticcastrationresistantprostatecancerwithbonemetastasestreatedbyenzalutamide |